Detalhe da pesquisa
1.
Immunotherapy with anti-GD2 monoclonal antibody in infants with high-risk neuroblastoma.
Int J Cancer
; 152(2): 259-266, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913764
2.
Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.
Int J Cancer
; 153(12): 2019-2031, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37602920
3.
Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma.
Pediatr Blood Cancer
; 70(2): e30075, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36349892
4.
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Cancer
; 128(21): 3775-3783, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36101004
5.
Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma.
Pediatr Blood Cancer
; 68(10): e29265, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34331515
6.
Mandibular metastases in neuroblastoma: Outcomes and dental sequelae.
Pediatr Blood Cancer
; 68(4): e28918, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33507629
7.
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience.
Pediatr Blood Cancer
; 67(8): e28319, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32543116
8.
Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma.
Pediatr Blood Cancer
; 67(9): e28364, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32608559
9.
Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric survivors of high-risk neuroblastoma.
Pediatr Blood Cancer
; 66(11): e27960, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31407504
10.
Treatment and outcome of adult-onset neuroblastoma.
Int J Cancer
; 143(5): 1249-1258, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29574715
11.
Dose-escalation is needed for gross disease in high-risk neuroblastoma.
Pediatr Blood Cancer
; 65(7): e27009, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29469198
12.
Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.
J Pediatr Hematol Oncol
; 40(6): e394-e396, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28816801
13.
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
Int J Cancer
; 140(2): 480-484, 2017 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27649927
14.
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Pediatr Blood Cancer
; 64(8)2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28111925
15.
Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.
J Pediatr Hematol Oncol
; 39(7): 547-554, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28692550
16.
Re-thinking transplant for neuroblastoma.
Pediatr Blood Cancer
; 68(6): e28961, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33661565
17.
Osteochondroma in long-term survivors of high-risk neuroblastoma.
Cancer
; 121(12): 2090-6, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25728463
18.
Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
Int J Cancer
; 135(9): 2199-205, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24644014
19.
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.
Cancer
; 120(13): 2050-9, 2014 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24691684
20.
Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year Experience.
Pract Radiat Oncol
; 14(3): e226-e232, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310488